Pure Tricaprin C10

The MCT Oil That Actually Targets Heart Health.

Most MCT oils are blends containing varying amounts of medium-chain triglycerides — usually mostly C8, with smaller amounts of C10 and C12. Tricaprin is different: it is the specific C10 triglyceride being studied for cardiovascular metabolism and how cells handle stored lipids.

View Pure Tricaprin See the Research
Nature Cardiovascular Research, 2025
“Remarkable long-term survival and durable recovery of heart failure”

In diagnosed TGCV [a rare fat-storage disease of the heart and blood vessels that can lead to heart failure] patients, supplemental tricaprin was linked with long-term survival and heart-failure recovery signals — a clear human reason C10 is getting attention in heart-metabolism research.

Read the Nature study ↗
HelloPharmacist introduces

The First 100% Pure Tricaprin (C10) Supplement in the United States.

HelloPharmacist 100% Pure Tricaprin C10 bottle
120Softgels per bottle
1gPure C10 per serving
FastAbsorption softgel dosage form
4Ingredients: Tricaprin, Gelatin, Glycerin & Water

Brought to you by HelloPharmacist, this is not another generic MCT oil blend dressed up with a C10 mention. It is 100% pure Tricaprin C10 — a bigger, cleaner spotlight on the C10 supplement details that matter: 120 softgels, 1 gram per serving, fast absorption, and only four ingredients.

USPUSP Grade
3PVThird Party Verified
GMPGMP Quality
An MCT Oil unlike all the others

Pure C10. Zero blend noise. HelloPharmacist 100% Pure Tricaprin puts the spotlight where it belongs: on the exact C10 triglyceride people are reading about in heart-metabolism research — not C8-heavy formulas, coconut-oil confusion, or vague “proprietary” MCT positioning.

Shop 100% Pure Tricaprin on Amazon

Want to know why C10 Tricaprin is so special? Keep reading — the next sections break down the science, the MCT comparison, and what makes pure C10 different.

Explore the mechanism

Why the heart research is different.

MCT means medium-chain triglycerides — a family of fats that includes C8, C10, and C12. Most “MCT oil” is built around fast-burning C8. Tricaprin C10 is different: it is the isolated C10 triglyceride studied in cardiovascular lipid-handling research, where purity matters because mixed oils can dilute C10 and compete for metabolism.

Tap the + to explore the science
3D Human Heart

Direct Heart Delivery

Bulky fats — especially longer-chain fats like C12 and traditional dietary fats — rely more heavily on transporter systems before they can be used inside mitochondria. Pure C10 is different because it is less dependent on that bottleneck, which is one reason it stands out in cardiovascular metabolism research.

Targeting Stubborn Heart Fat

Pure C10 acts as a metabolic key that triggers myocardial lipolysis. It effectively reactivates your heart tissue, forcing it to break down and burn off accumulating cellular fat.

The Artery Plaque Research

This is the science catching global attention. In published medical case reports (TGCV), dietary Tricaprin was directly linked to the visible regression of plaque buildup inside coronary arteries.

Why Mixed Blends Fail

It’s about metabolic competition. In generic MCT oils, fast-burning C8 hogs your body's attention and drowns out the C10. To effectively reach your cardiovascular system, Tricaprin must be taken in 100% pure isolation.

Tricaprin C10 is not regular MCT oil. The cardiovascular research centers on isolated, pure C10 — not C8-heavy blends, coconut oil, or “MCT” in name only. True Tricaprin C10 supplements are rare, so check the label and choose the exact ingredient studied.

Why C10 Is Different

Pure C10 vs. The MCT Oil Crowd.

Tricaprin C10 refers to a specific molecule, not a generic MCT category. Many MCT products are C8-forward blends with only some C10 included. The cardiovascular research attention is focused on isolated C10 — which is why purity, labeling, and documentation matter.

The big idea

C10 is the callout. Everything else is the blend.

Most MCT oil means a mix of medium-chain triglycerides — commonly C8 first, with C10 often far behind. Tricaprin strips away the blend and makes 100% pure C10 the main event: the specific triglyceride studied for myocardial lipolysis, coronary lipid handling, and TGCV-focused cardiovascular outcomes.

01

MCT is a family — not a formula

C8, C10, and C12 are all medium-chain triglycerides, but they do not tell the same story in the body or in the research.

02

C8 dominates most blends

Many MCT oils are designed around fast-burning C8, so the C10 may be small, variable, or buried behind the “MCT” label.

03

More C10 is not the same as pure C10

Even if a mixed product adds C10, the other MCTs still compete for attention and metabolism. Purity keeps the formula focused on C10.

04

C10 owns the heart-research lane

The published TGCV cardiovascular research centers on tricaprin/C10 — not generic coconut oil, not C8, and not mixed MCT blends.

Coconut oil Broad fat profile

Mostly not C10. Natural, variable, and not an isolated tricaprin delivery system.

Generic MCT oil C8 usually runs the show

Often quick-energy focused, with C10 present only as a smaller or inconsistent supporting ingredient.

Pure Tricaprin C10 100% C10. No blend noise.

The exact C10 triglyceride spotlighted in TGCV cardiovascular lipid-handling research.

C10 callout

Don’t Buy the Label. Look for the C10.

“MCT oil” can mean very different formulas. The question is not whether a bottle mentions C10 — it is whether C10 is the star or just a trace player competing with faster-burning fats.

Mixed products

Coconut + generic MCT oils

  • Broad fat profiles or C8-heavy quick-energy blends.
  • May list C10, but the amount can be small, variable, or under 10%.
  • C8 and other fats compete for metabolism, making C10 less of the main event.
Pure Tricaprin

Pure Tricaprin C10

  • 100% isolated tricaprin — not a generic MCT blend.
  • The C10 triglyceride featured in TGCV cardiovascular lipid-handling research.
  • Verify pure C10. Demand a COA. Skip C8/C10 blends.
C8Fast fuel / keto positioning
C10Tricaprin heart-metabolism research focus
C12Often part of blends, not the C10 story
Evidence Atlas

Tricaprin Research, Translated.

This research library records tricaprin/C10 studies for review, separating direct cardiovascular research from TGCV background papers and updating the collection as new published research becomes available.

❤️
Plain-English takeaway

The strongest evidence is not “general heart health.” It is TGCV-specific.

Human tricaprin research is concentrated in triglyceride deposit cardiomyovasculopathy (TGCV), a rare diagnosed condition where heart and blood-vessel cells accumulate triglycerides because intracellular fat breakdown is impaired. In that setting, tricaprin has shown promising signals for myocardial lipolysis, heart-failure recovery, and coronary lesion regression. Researchers are also exploring how C10-focused lipid metabolism may relate to broader cardiovascular health questions, including heart-failure recovery and the removal of accumulated lipids from heart and artery tissues.

1 randomized TGCV trial
5 human TGCV treatment reports
3 preclinical C10 models
21 verified research links
Strongest human signal

Long-term survival & heart-failure recovery

Registry studies in diagnosed TGCV patients reported durable recovery markers and long-term survival in tricaprin-treated patients.

Nature Cardiovascular Research →
Best controlled evidence

Randomized Phase IIa mechanism trial

CNT-01 improved BMIPP washout rate in idiopathic TGCV, supporting improved myocardial lipolysis over 8 weeks.

Read RCT →
Most visual result

Coronary lesion regression case report

Two TGCV patients with refractory angina improved after tricaprin, with coronary CT angiography showing lesion regression.

Read EHJ report →
Verified study library

Direct tricaprin studies + TGCV context papers

Human registry 2025

Long-term survival and durable recovery of heart failure in patients with TGCV treated with tricaprin

Nature Cardiovascular Research

Layman takeaway: In diagnosed TGCV, registry data reported durable heart-failure recovery and long-term survival in patients who received supplemental tricaprin.

Most important human signal so far, but still rare-disease registry evidence—not proof for ordinary coronary disease.

Open source ↗
Randomized Phase IIa 2022

¹²³I-BMIPP scintigraphy shows CNT-01 (tricaprin) improves myocardial lipolysis in idiopathic TGCV

Annals of Nuclear Cardiology

Layman takeaway: In 17 idiopathic TGCV patients, 8 weeks of CNT-01 improved BMIPP washout rate, a marker of myocardial triglyceride breakdown.

Clinical measures did not significantly change during the short 8-week window, so this is mechanism proof more than symptom proof.

Open source ↗
Human case report 2023

Remarkable regression of diffuse coronary atherosclerosis in patients with TGCV

European Heart Journal

Layman takeaway: Two TGCV patients with refractory angina had symptom improvement and imaging-reported coronary lesion regression after dietary tricaprin.

Visually compelling, but a two-patient case report—best framed as a signal, not a guarantee.

Open source ↗
Imaging case report 2023

¹H-MRS evaluation after CNT-01 (tricaprin/trisdecanoin) administration in idiopathic TGCV

Endocrinology, Diabetes & Metabolism Case Reports

Layman takeaway: A TGCV case report found myocardial triglyceride content decreased and BMIPP washout improved after 8 weeks of CNT-01.

Helpful because it translates the mechanism into a noninvasive imaging marker in a real patient.

Open source ↗
ACS case report 2024

Acute coronary syndrome in a 40-year-old man with TGCV

CJC Open

Layman takeaway: A severe young-patient TGCV case used standard care plus tricaprin, highlighting how TGCV can masquerade as hard-to-treat coronary disease.

Important clinically, but treatment was combined with coronary bypass surgery, so effects cannot be assigned to tricaprin alone.

Open source ↗
Mouse model 2018

Tricaprin rescues myocardial abnormality in a mouse model of TGCV

Journal of Oleo Science

Layman takeaway: In an ATGL-deficient TGCV mouse model, tricaprin improved myocardial abnormalities and supported the clinical development path.

Preclinical proof-of-concept; mouse results should not be treated as human outcomes.

Open source ↗
Proteomics mechanism 2020

Effect of tricaprin on cardiac proteome in a mouse model for TGCV

Journal of Oleo Science

Layman takeaway: Follow-up mouse proteomics work explored how tricaprin changes heart-protein expression in the TGCV model.

Useful for mechanism, not a clinical efficacy claim.

Open source ↗
Vascular animal model 2023

Tricaprin can prevent the development of abdominal aortic aneurysm by attenuating aortic degeneration

Biomedicine & Pharmacotherapy

Layman takeaway: In a rat AAA model, C10-TG suppressed aneurysm development and rupture, while C8-TG did not show the same effect.

Vascular—not heart-failure—research, and still preclinical.

Open source ↗
Human trial protocol 2025

First-in-Human Abdominal Aortic Aneurysms Trial with Tricaprin (F-HAAAT)

CJC Open

Layman takeaway: A first-in-human AAA study protocol is testing oral tricaprin in small abdominal aortic aneurysms.

Protocol only—no efficacy results yet. Included because it is direct cardiovascular tricaprin research.

Open source ↗
Pharmacokinetics 2017

Plasma capric acid concentrations during short-term oral synthetic tricaprin administration in dogs

Analytical Sciences

Layman takeaway: Dog pharmacokinetic work showed dose-dependent capric-acid exposure after oral synthetic tricaprin and rapid clearance within hours.

Not a heart-outcome study; useful background for how C10 appears in circulation after dosing.

Open source ↗
TGCV prognosis 2023

Overall survival rate of patients with triglyceride deposit cardiomyovasculopathy

JACC: Advances

Layman takeaway: Registry survival work shows why TGCV is treated as a serious rare cardiovascular disorder needing targeted study.

Context study; tricaprin-treated patients were excluded from this survival analysis.

Open source ↗
Mechanism / subtypes 2024

Distinct myocardial triglyceride lipolysis pathways in primary and idiopathic TGCV

ESC Heart Failure

Layman takeaway: Helps separate primary vs idiopathic TGCV biology and explains why myocardial lipolysis markers matter.

Context for mechanism and patient selection, not direct consumer guidance.

Open source ↗
Diagnostic criteria 2020

The Diagnostic Criteria 2020 for triglyceride deposit cardiomyovasculopathy

Annals of Nuclear Cardiology

Layman takeaway: Defines the disease framework used in TGCV research, including imaging criteria tied to myocardial fat metabolism.

Important guardrail: these findings apply to diagnosed TGCV, not casual self-diagnosis.

Open source ↗
Rare disease review 2019

Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder

Orphanet Journal of Rare Diseases

Layman takeaway: A broad clinical overview linking myocardial and coronary triglyceride deposition with heart failure and coronary disease.

Best background paper for understanding TGCV before reading treatment studies.

Open source ↗
Stent restenosis cohort 2020

TGCV and drug-eluting stent restenosis among patients with diabetes

JAMA Network Open

Layman takeaway: Suggests TGCV may be relevant in difficult coronary disease cases, especially recurrent restenosis in diabetes.

Context paper; not a tricaprin treatment trial.

Open source ↗
Hemodialysis cohort 2021

Prevalence and clinical outcomes of TGCV among haemodialysis patients

Heart

Layman takeaway: Shows TGCV can be found in high-risk cardiovascular populations such as patients on hemodialysis.

Context paper; useful for prevalence and risk discussion.

Open source ↗
ACS / PCI prevalence 2024

Prevalence of TGCV among acute coronary syndrome patients undergoing PCI

European Heart Journal: Acute Cardiovascular Care

Layman takeaway: Looks for TGCV in acute coronary syndrome patients undergoing PCI, helping frame how often it may be missed.

Context paper; included to support the diagnosis-first framing.

Open source ↗
Foundational imaging 2015

Cardiomyocyte steatosis and defective BMIPP washout in genetic ATGL deficiency

European Heart Journal

Layman takeaway: Foundational imaging observation connecting ATGL deficiency, cardiac fat buildup, and abnormal BMIPP washout.

Pre-tricaprin foundation for later BMIPP treatment endpoints.

Open source ↗
Genetics 2014

Genetic mutations in adipose triglyceride lipase and myocardial PPARγ up-regulation in TGCV

Biochemical and Biophysical Research Communications

Layman takeaway: Clarifies the genetic/metabolic basis of primary TGCV involving adipose triglyceride lipase dysfunction.

Mechanistic background for why a lipid-handling therapy was pursued.

Open source ↗
Coronary pathology 2014

A novel type of human spontaneous coronary atherosclerosis with triglyceride deposition

European Heart Journal

Layman takeaway: Introduced coronary artery triglyceride deposition as a distinct pathology in this TGCV research line.

Foundational context for the later coronary regression case report.

Open source ↗
Original disease report 2008

Triglyceride deposit cardiomyovasculopathy

New England Journal of Medicine

Layman takeaway: The original report that named and described TGCV as a distinct cardiomyovascular disease entity.

Disease discovery paper; not a tricaprin study.

Open source ↗
Educational note: The direct tricaprin/C10 links are presented alongside TGCV diagnostic, prognosis, and coronary-disease context papers. Tricaprin is a dietary supplement, not an FDA-approved treatment for heart disease. This section is educational and should not be read as medical advice.

HelloPharmacist

You Ask. We Answer.

Dr. Brian Staiger, PharmD, founder of HelloPharmacist

Pharmacist-owned. Pharmacist-formulated. Built around consumer trust.

HelloPharmacist is a North Carolina-based, pharmacist-owned company founded by Dr. Brian Staiger, PharmD. Every HelloPharmacist formula is created with pharmacist oversight, practical clinical judgment, and a commitment to helping people understand exactly what they are taking.

15+ Years of experience

Anchored by Dr. Staiger’s background helping consumers navigate medications, supplements, and evidence-based wellness decisions.

PharmD Licensed pharmacist leadership

Formulas are developed by a pharmacist — not by a faceless supplement label or generic marketplace brand.

NC Based in North Carolina

A real pharmacist-owned company with an educational mission and an accessible team behind the product.

Have a question for a licensed pharmacist? Visit HelloPharmacist.com and we’re happy to help.

Visit HelloPharmacist.com

Looking for Pure Tricaprin?

Don't settle for diluted MCT blends. Get the focused C10 supplement brought to you by HelloPharmacist.

View 100% Pure Tricaprin on Amazon
🛒 Buy Pure Tricaprin Today ? Supplement FAQ